Creating, facilitating, and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe
PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available
PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.
This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA.
Patient group input requested for a new Joint Assessment on a medicinal product for cerebral adrenoleukodystrophy (CALD).
EUnetHTA deems patient involvement very important in the production of Joint Assessment